8-K: Doximity Co-Founder Dr. Nathan Gross Transitions from Chief Strategy Officer to Advisor Role

Doximity, Inc. announces that co-founder Dr. Nathan Gross will step down as Chief Strategy Officer to become an advisor, effective June 16, 2025, maintaining his connection to the company's strategic direction.

Summary

• Dr. Nathan Gross, a co-founder of Doximity, Inc., will transition from his role as Chief Strategy Officer to an advisor to the company.
• His last day in the Chief Strategy Officer role will be June 16, 2025.
• Dr. Gross will provide advisory services under an Independent Contractor Agreement, dated June 13, 2025.
• As compensation for his advisory services, his restricted stock unit and option awards will continue to vest through September 2025.
• Dr. Gross will not receive any cash compensation for his advisory services.
• The company expects to file a copy of the Advisor Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2025.
• A blog post regarding Dr. Gross's transition was released on June 13, 2025, and furnished as Exhibit 99.1 to the 8-K filing.

Sentiment

Score: 8

Explanation: The sentiment is overwhelmingly positive, framing the co-founder's departure as a smooth transition to an advisory role, with strong endorsements for the company's future and current team from both the CEO and the departing officer. No negative implications or performance issues are mentioned.

Positives

• Dr. Nathan Gross will remain an active advisor to Doximity, ensuring continued access to his expertise in digital health.
• The transition is framed positively by both CEO Jeff Tangney and Dr. Gross, emphasizing a smooth 'passing the baton' to a 'world-class' team.
• Dr. Gross expressed continued excitement about Doximity's future, highlighting transformative products in workflow, news, and AI, and a roadmap to become a 'generational company'.
• The company's discipline in earning partner trust, insisting on win-wins for members, and running lean and profitable is noted as empowering its vision.

Risks

• The departure of a co-founder and Chief Strategy Officer, even with an advisory role, could lead to a loss of day-to-day strategic leadership and institutional knowledge.

Future Outlook

The document highlights Doximity's strong product roadmap, including advancements in workflow, news, and AI, which are seen as transformative for the healthcare industry. Management and the departing CSO express confidence in the company's potential to become a 'generational company' by staying true to its 'Physicians First compass' and maintaining a disciplined, profitable operational approach.

Management Comments

• Jeff Tangney (CEO): "He [Nate] was then, and remains now, a human encyclopedia of digital health, a physician tech enthusiast who really understands how it all fits together. That’s why we’re proud to keep Nate as an active advisor. He ain’t done fixing healthcare yet."
• Dr. Nate Gross: "The products you’re building in workflow, news, and AI are transformative to the healthcare industry. And the product roadmap I’ve watched take shape over the past year convinces me Doximity has the ingredients to become a generational company while staying true to our Physicians First compass."
• Dr. Nate Gross: "Your discipline—in earning partners trust, insisting on win-wins for our members, and running lean and profitable—empowers us to continue to serve the medical profession and act on our vision."
• Dr. Nate Gross: "The team developing and leading this work is world-class and keeps leveling up every quarter. That combination makes this a rare, genuinely good moment for a co-founder to pass the baton to immensely talented colleagues and create space for a new challenge."

Industry Context

Doximity operates in the digital health sector, providing a platform for physicians. The departure of a co-founder and Chief Strategy Officer, described as a 'human encyclopedia of digital health,' underscores the ongoing evolution and strategic shifts within the healthcare technology landscape, where expertise in integrating technology with medical practice is highly valued.

Management Changes

Related Party Transactions

• An Independent Contractor Agreement (Advisor Agreement) has been entered into between Doximity, Inc. and Dr. Nathan Gross, a co-founder and former Chief Strategy Officer, for advisory services. This arrangement includes the continued vesting of his restricted stock unit and option awards through September 2025 without cash compensation.

Stakeholder Impact

• Shareholders: The transition of a co-founder and CSO to an advisory role could be viewed positively as it retains expertise while allowing for new leadership, potentially ensuring strategic continuity. However, the loss of day-to-day involvement from a key executive could also introduce uncertainty.
• Employees: The internal team is highlighted as 'world-class' and 'leveling up,' suggesting a smooth internal transition and confidence in the existing leadership to continue the company's mission.
• Customers (Physicians): The company reaffirms its 'Physicians First compass' and commitment to building transformative products, indicating no change in focus for its user base.
• Partners: The company's discipline in 'earning partners trust' is emphasized, suggesting continued strong relationships.

Next Steps

• Doximity expects to file a copy of the Independent Contractor Agreement (Advisor Agreement) as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2025.

Key Dates

Keywords

Doximity, DOCS, Chief Strategy Officer, Nathan Gross, executive change, healthcare technology, digital health, SEC filing, 8-K, corporate governance, advisor